Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
- Evaluate the ability of the microculture kinetic (MiCK) assay to predict the outcome of
patients with ovarian, fallopian tube, or primary peritoneal adenocarcinoma treated
with first-line chemotherapy.
- Evaluate the ability of the MiCK assay to guide chemotherapy in a third-line,
refractory treatment setting (exclusive of anti-vascular endothelial growth factor) in
OUTLINE: Patients are stratified according to prior chemotherapy (no [stratum I] vs yes
Tumor tissue and/or effusion specimens are collected at baseline. Specimens are examined by
the microculture kinetic (MiCK) assay and immunocytochemical or flow cytometry assay.
MiCK assay results do not influence treatment for stratum I patients. Stratum II patients
may receive treatment based on MiCK assay results for tumor sensitivity to specific
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Correlation of a statistically significant discriminator of sensitivity with complete response rate
Vladimir D. Kravtsov, MD
|Southeastern Gynecologic Oncology, LLP - Northside||Atlanta, Georgia 30342|